Chemistry:ZED1227
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C26H36N6O6 |
| Molar mass | 528.610 g·mol−1 |
ZED1227 is a transglutaminase 2 (TG2) inhibitor developed by Zedira GmbH for celiac disease[1][2] and nonalcoholic steatohepatitis.[3]
References
- ↑ Schuppan, Detlef; Mäki, Markku; Lundin, Knut E.A.; Isola, Jorma; Friesing-Sosnik, Tina; Taavela, Juha; Popp, Alina; Koskenpato, Jari et al. (1 July 2021). "A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease". New England Journal of Medicine 385 (1): 35–45. doi:10.1056/NEJMoa2032441. PMID 34192430.
- ↑ Büchold, Christian; Hils, Martin; Gerlach, Uwe; Weber, Johannes; Pelzer, Christiane; Heil, Andreas; Aeschlimann, Daniel; Pasternack, Ralf (17 May 2022). "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease". Cells 11 (10): 1667. doi:10.3390/cells11101667. PMID 35626704.
- ↑ "CTG Labs - NCBI". https://clinicaltrials.gov/study/NCT05305599?start=2019-11-03_&aggFilters=funderType:industry,phase:2%203&limit=100&cond=NASH&rank=93.
 |  |
